New Delhi, Sept. 29 -- India remains largely insulated from pharma tariffs and H1B visa restrictions, said Seemant Shukla, CEO of Quantum AMC. In an interview with Mint, he said that the bigger risk would be if IT services exports faced tariffs. However, the government is mitigating shocks with tax cuts, goods and services tax (GST) reductions, and liquidity support, Shukla added.

Edited excerpts:

India's pharma exports are primarily into generic drugs, which are currently outside the ambit of the tariff order. Generic drugs see high price erosion as they come once the innovator drug's patent expires. Even if one were to assume a similar tariff could eventually come to generic drugs, its pricing would continue to be competitive. India h...